Once-Daily Omeprazole/Sodium Bicarbonate Heals Severe Refractory Reflux Esophagitis with Morning or Nighttime Dosing
- 22 January 2014
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (1) , 146-162
Abstract
Morning dose or twice-daily proton pump inhibitor (PPI) use is often prescribed to heal severe reflux esophagitis.Keywords
This publication has 29 references indexed in Scilit:
- The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazoleAlimentary Pharmacology & Therapeutics, 2013
- The Mayo Dysphagia Questionnaire-30: Documentation of Reliability and Validity of a Tool for Interventional Trials in Adults with Esophageal DiseaseDysphagia, 2009
- Prevalence of Barrett’s esophagus in patients with moderate to severe erosive esophagitisWorld Journal of Gastroenterology, 2008
- Comparison of the effects of immediate‐release omeprazole oral suspension, delayed‐release lansoprazole capsules and delayed‐release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night‐time GERD symptomsAlimentary Pharmacology & Therapeutics, 2007
- The Development and Validation of an Endoscopic Grading System for Barrett’s Esophagus: The Prague C & M CriteriaGastroenterology, 2006
- Review of immediate-release omeprazole for the treatment of gastric acid-related disordersExpert Opinion on Pharmacotherapy, 2005
- Comparison of the effects of immediate‐release omeprazole powder for oral suspension and pantoprazole delayed‐release tablets on nocturnal acid breakthrough in patients with symptomatic gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 2005
- A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO studyAlimentary Pharmacology & Therapeutics, 2005
- CYP2C19 pharmacogenetics in the clinical use of proton‐pump inhibitors for gastro‐oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptomsAlimentary Pharmacology & Therapeutics, 2003
- Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classificationGut, 1999